within Pharmacolibrary.Drugs.ATC.D;

model D08AA02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D08AA02</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Aminoacridine (known also as proflavine or 3,6-diaminoacridine) is an acridine derivative that was historically used as an antiseptic for the treatment of wounds and for topical infection control. It is primarily a topical antiseptic with bacteriostatic effects. Aminoacridine is largely obsolete today and is not widely approved for systemic therapeutic use.</p><h4>Pharmacokinetics</h4><p>No modern human pharmacokinetic studies are available for aminoacridine. No published data in peer-reviewed literature were identified reporting quantitative pharmacokinetic parameters (bioavailability, clearance, compartmental models, etc.) for systemic administration of aminoacridine in humans.</p><h4>References</h4><ol><li><p>Silvander, M, et al., &amp; Sköld, T (2006). A new water-based topical carrier with polar skin-lipids. <i>Lipids in health and disease</i> 5 12–None. DOI:<a href=\"https://doi.org/10.1186/1476-511X-5-12\">10.1186/1476-511X-5-12</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16672068/\">https://pubmed.ncbi.nlm.nih.gov/16672068</a></p></li><li><p>Martiel, I, et al., &amp; Mezzenga, R (2015). Oil and drug control the release rate from lyotropic liquid crystals. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 204 78–84. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2015.02.034\">10.1016/j.jconrel.2015.02.034</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25744826/\">https://pubmed.ncbi.nlm.nih.gov/25744826</a></p></li><li><p>Zeng, M, et al., &amp; Campochiaro, PA (2017). The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization. <i>Journal of molecular medicine (Berlin, Germany)</i> 95(4) 417–429. DOI:<a href=\"https://doi.org/10.1007/s00109-016-1498-9\">10.1007/s00109-016-1498-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28004126/\">https://pubmed.ncbi.nlm.nih.gov/28004126</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D08AA02;
